Clinical trials: Mucorales Infection
Aspergillos, Mucormye
Assessment of [18F]-Fluorocellobiose ([18F]FCB) Pharmacokinetics in Healthy Volunteers and Subjects With Invasive Mold Infections
Background: Fungal infections can cause serious disease in the lungs and other parts of the body. About 3.8 million people die with fungal infections each year.
- Conditions
- Aspergillos, Mucormye, Dimorphic, Other Molds
- Trial name
- NCT07704333
- Testing
- [18F]-Fluorocellobiose ([18F]FCB)
- Where
- United States
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- National Institutes of Health Clinical Center (CC)
Mucorales Infection, Mucormycosis
Biomarkers for Invasive Mucormycosis
Mucormycosis (MM) is one of the main invasive fungal infection (IFI), and is determined by filamentous fungi belonging to the order of Mucorales, with a mortality rate ranging from 20 to 60% according to localization.
- Trial name
- BIM (NCT05406037)
- Testing
- Venous sample
- Where
- France
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University Hospital, Lille
Rhinocerebral Mucormycosis
Endoscopic Surgical Treatment of Rhino-Sinusal Mucormycosis
Radical endoscopic transnasal surgery associated with medical treatment with liposomal amphotericine B may increase the local control of Rhino-Sinusal Mucormycosis and the survival rate.
- Trial name
- MICCA (NCT02226705)
- Testing
- Multiple transnasal endoscopic surgeries
- Where
- France
- Volunteers
- 11 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Aspergillosis, Mucormycosis
Post Marketing Surveillance (PMS) Study of Cresemba in Korea.
The purpose of this study is to observe safety and effectiveness of Cresemba in patients with invasive Aspergillosis or invasive Mucormycosis in Korea during the post-marketing surveillance period as required by Ministry of Food…
- Trial name
- NCT04744454
- Testing
- Isauvuconazole group
- Where
- South Korea
- Volunteers
- 94 people
- Sponsor
- Pfizer
Mucormycosis; Rhinocerebral (Etiology), Post COVID-19 Condition, Unspecified
Post-COVID-19 Mucormycosis in Critical Care
Background: Mucormycosis is a life-threatening opportunistic fungal infection. Despite mucormycosis having existed for decades, it has gained notice of its widespread in many parts of the world during the second wave of the…
- Trial name
- NCT05911035
- Where
- Egypt
- Volunteers
- 150 people
- Sponsor
- Zagazig University
Mucormycosis
Mucormycosis Clinical Core for the MUCOR-ADVANCE P01 Project
To collect data and samples from participants with cancer who also have invasive mucormycosis, invasive aspergillosis, bacterial pneumonia, or a risk for fungal infection.
- Trial name
- NCT06878144
- Testing
- Mucormycosis
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- M.D. Anderson Cancer Center
Invasive Mold Infections
A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Patients With Invasive Mold Infections.
The purpose of this study is to evaluate the efficacy and safety of fosmanogepix (administered IV or oral) for the treatment of adult patients with invasive mold infections.
- Trial name
- NCT06925321
- Testing
- Fosmanogepix IV infusion, Standard of care antifungal therapy, Fosmanogepix oral tablet
- Where
- 84 sites in United States, Australia and 13 more
- Volunteers
- 234 people
- Sponsor
- Basilea Pharmaceutica
Mucormycosis
Mucormycosis in ICU
Mucormycosis is an invasive fungal infection affecting patients with various clinical conditions especially patients with heavy immunosuppression or patients with trauma or extensive burns.
- Trial name
- ZygoRéa (NCT03387696)
- Where
- 21 sites in France
- Volunteers
- 74 people
- Sponsor
- University Hospital, Grenoble
Pulmonary Mucormycosis
Chest CT Scan in Pulmonary Mucormycosis: Prognostic Value
Invasive pulmonary fungal infections caused by Mucorales are rare but severe and rapidly progressive, affecting immunocompromised patients.
- Trial name
- RadioMucor (NCT07339800)
- Where
- France
- Volunteers
- 80 people
- Sponsor
- University Hospital, Strasbourg, France
Pulmonary Mucormycosis
Antifungal Drugs in Pulmonary Mucormycosis
Pulmonary mucormycosis (PM) poses a substantial clinical challenge, particularly among immunocompromised patients. The aim of the study is to determine the effectiveness and safety of administering AmBisome at a dose of…
- Trial name
- NCT06756191
- Testing
- Combination therapy group, Liposomal Amphotericin B
- Volunteers
- 312 people
- Sponsor
- Bin Cao
Mucormycosis
COVID-19 Associated Mucormycosis: A Multidisciplinary Dilemma in Assiut University Hospital
We aimed to describe the frequency; presentations, predictors, in-hospital outcome of mucormycosis patients in the scope of COVID-19.
- Trial name
- NCT05074043
- Testing
- antiviral, surgical
- Where
- Egypt
- Volunteers
- 433 people
- Sponsor
- Assiut University
Invasive Fungal Infections
A Bioequivalence Study of APX001 High-load and Low-load Tablets
A study to learn about the bioequivalence (the biochemical similarity of two medicines that share the same active ingredient and desired outcome for patients) of the study medicine called APX001 in healthy participants.
- Trial name
- NCT05491733
- Testing
- APX001, APX001A
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Basilea Pharmaceutica
Mucormycosis
Mucorales PCR Screening in At-risk Hematology Patients
Patients with leukemia are treated with intensive chemotherapy and often have to undergo a stem cell transplantation which makes their immune system extremely vulnerable.
- Trial name
- MUCOPS (NCT05925660)
- Testing
- Mucorales PCR (MucorGenius, PathoNostics, Maastricht, The Netherlands)
- Where
- Belgium
- Volunteers
- 200 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Invasive Mucormycosis, Invasive Aspergillosis
A Study to Evaluate Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Participants
The purpose of this study was to evaluate the safety, tolerability, and efficacy of isavuconazonium sulfate in pediatric participants.
- Trial name
- NCT03816176
- Testing
- Isavuconazonium sulfate
- Where
- 10 sites in United States, Belgium and 1 more
- Volunteers
- 31 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Mucormycosis
Prospective Evaluation of a New Molecular Tool for Early Diagnosis of Mucormycosis
This Study evaluates the performance (sensitivity, specificity, positive and negative predictive value values and likelihood ratios) of the DNA detection test for the diagnosis of mucormycosis by comparing it to the routine tests…
- Trial name
- MODIMUCOR (NCT02845934)
- Testing
- blood sample
- Where
- 10 sites in France
- Volunteers
- 248 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Covid-19
Characterization of Fungal Infections in COVID-19 Infected and Mechanically Ventilated Patients in ICU
Characterization of fungal infections in COVID-19 infected and mechanically ventilated patients in ICU
- Trial name
- MY-CO-VID (NCT04368221)
- Where
- 22 sites in France
- Volunteers
- 576 people
- Sponsor
- Rennes University Hospital
Mucormycosis
Rehabilitation With an Obturator in Maxillary Defects
During the COVID-19 pandemic, there was a lot of reporting of COVID-19-associated mucormycosis cases. Managing this condition posed a new challenge to clinicians.
- Trial name
- NCT06515743
- Testing
- Obturator Prosthetic Rehabilitation
- Where
- Egypt
- Volunteers
- 42 people
- Sponsor
- Menoufia University
COVID-19, Mucormycosis
Ocular Manifestation and Related Risk Factors of Covid-19 Associated Mucormycosis: a Multicenter Study in Iran
Coronavirus disease 2019 (COVID-19) infection caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may manifest as a variety of disease patterns, ranging from mild to life-threatening pneumonia.
- Trial name
- NCT05097664
- Where
- Iran
- Volunteers
- 250 people
- Sponsor
- Isfahan University of Medical Sciences
Covid19, Mucormycosis
Mucormycosis in COVID-19
The purpose is to allow phsyician reporters to contribute to MUNCO registry. Mucormycosis in COVID-19 is a rapidly escalating medical emergency reported in high numbers in India during the ongoing coronavirus surge.
- Conditions
- Covid19, Mucormycosis, Aspergillosis, Candida Infection
- Trial name
- MUNCO (NCT04935463)
- Where
- United States
- Volunteers
- 728 people
- Sponsor
- Montefiore Medical Center
Mycoses
Descriptive Epidemiology on Management of Mucormycosis
This is an observational chart review of all patients with confirmed and probable diagnosis of mucormycosis at 19 centers across Indian hospital. Data will collect using a standardized CRF.
- Trial name
- NCT03429023
- Where
- 13 sites in India
- Volunteers
- 500 people
- Sponsor
- Fungal Infection Study Forum